Drug intelligence / Profile preview

atezolizumab + nab-paclitaxel + tocilizumab

Development stage: Unknown
Lead developer: Roche
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous

Overview

Atezolizumab + nab-paclitaxel + tocilizumab is an experimental combination regimen investigated in oncology clinical trials. **Atezolizumab** is a monoclonal antibody that inhibits programmed death ligand 1 (PD-L1), thereby releasing inhibition of the anti-tumor immune response. **Nab-paclitaxel** (nanoparticle albumin-bound paclitaxel) is a chemotherapy agent that stabilizes microtubules and inhibits cell division. **Tocilizumab** is a monoclonal antibody targeting the interleukin-6 receptor (IL-6R), used to suppress inflammation. The combination is being studied for enhanced immunomodulatory and anti-tumor effects, particularly in cancers where immune suppression and inflammation contribute to tumor progression[7].

Brand names: Tecentriq (atezolizumab)Actemra (tocilizumab)Abraxane (nab-paclitaxel)
Other names: atezolizumab + nab-paclitaxel + tocilizumab

Targets

IL-6R (Interleukin-6 receptor subunit alpha)CD274 (Programmed cell death protein 1 ligand 1)Microtubule

Beyond the preview

Go deeper on atezolizumab + nab-paclitaxel + tocilizumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on atezolizumab + nab-paclitaxel + tocilizumab.

Explore the full profile